Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis

Phase 2/3 Unknown 204 enrolled Faculty of Medicine, University of Indonesia

RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of this study is to determine the efficacy and safety of Beta-1,3/1,6-D-Glucan from mycelium extract of Ganoderma lucidum on ulcerative colitis

Timeline

Start: 2019-08
Primary completion: 2020-12
Completion: 2020-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	beta-glucan	Other / unclassified	180 mg	—

Beta-1,3/1,6-D-Glucan Ganoderma Lucidum on Ulcerative Colitis

Summary

Timeline

Drugs

Indications